

A3
cmcll.

--16. The use according to claim 6 for increasing NGF and BDNF.--

REMARKS

By the foregoing amendment to the specification, a cross-reference has been inserted beneath the title on Page 1.

Claim 7 has been amended to eliminate its multiple dependency.

New Claims 12-16 are directed to the subject matter excised from Claim 7.

Attached hereto is a "marked-up" version of the change made to Claim 7 by the foregoing amendment.

Early and favorable consideration of the claims is respectfully awaited.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6921

Date: September 18, 2001

Encl.: "Marked-up" version of the
change made to Claim 7

Joseph J. Bordvian
Joseph J. Bordvian
Agent for Applicants
Reg. No. 26,631

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 7 has been amended as follows:

7. The use according to any one of claims 1 to 6 claim 1 for increasing NGF and BDNF.